Galecto Inc - Asset Resilience Ratio
Galecto Inc (GLTO) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Galecto Inc (GLTO) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Galecto Inc's Asset Resilience Ratio has changed over time. See Galecto Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Galecto Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GLTO stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Galecto Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Galecto Inc Industry Peers by Asset Resilience Ratio
Compare Galecto Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
|
Concord Biotech Limited
NSE:CONCORDBIO |
Biotechnology | 18.00% |
|
Pharming Group NV
AS:PHARM |
Biotechnology | 7.13% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 56.48% |
Annual Asset Resilience Ratio for Galecto Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Galecto Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $17.13 Million | -- |
| 2023-12-31 | 30.57% | $11.69 Million | $38.23 Million | -6.92pp |
| 2022-12-31 | 37.49% | $27.44 Million | $73.19 Million | +6.70pp |
| 2021-12-31 | 30.79% | $37.63 Million | $122.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.60 Million | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more